慢性心力衰竭患者血清可溶性Fas配体和可溶性Fas受体水平

The serum levels of soluble Fas ligand and soluble Fas receptor in patients with chronic congestive heart failure

目的:分析血清可溶性Fas配体(sFasL)和可溶性Fas。受体(sFas)与慢性心力衰竭(CHF)的相关性。方法:采用酶联免疫吸附双抗体夹心法检测33例CHF患者(CHF组,心功能Ⅱ-Ⅳ级,NYHA血清sFasL和sFas浓度,并与18例心功能Ⅰ级(NYHA)组比较。结果:CHF与心功能Ⅰ级组间sFasL浓度无显著统计学差异[231.50±84.50(心功能Ⅱ级216.50±96.00,Ⅲ级226.80±85.70Ⅳ级244.00±73.00)vs.217.50±89.00pg/ml,P>0.05]。而CHF组血清sFas浓度显著高于心功能Ⅰ级组[1353.30±507.71(心功能Ⅱ级1154.85±371.20,Ⅲ级1412.88±493.62,Ⅳ级1875.67±806.10)vs.983.11±461.26pg/ml,P<0.05]。结论:血清sFasL与CHF无相关性。而血清sFas与CHF存在显著相关性。且sFas浓度增高的程度与CHF的严重程度相平行,sFas浓度增高可能在CHF发病机制中起重要作用。

Objective :To investigate the association of soluble Fas ligand (sFasL) and soluble Fas receptor (sFas) with human chronic congestive heart failure (CHF). Methods :The serum level of sFasL and sFas in 33 patients with CHF (13 in cardiac function class Ⅱ , 17 in class Ⅲ ,3 in class Ⅳ ,NYHA) was assessed with enzyme- linked immunosorbent assay,and was compared with that of 18 age,gender and blood pressure - matched patients with cardiac function class Ⅰ (NYHA). Results: There was no difference in the level of sFasL between the two groups [ CHF group: 231. 50 ± 84. 50 (cardiac function class Ⅱ 216.50 ± 96.00, class Ⅲ 226.80 ± 85.70, claas Ⅳ 244.00 ± 73.00) vs. cardiac function class Ⅰ group: 217. 50 ± 89. 00 pg/ml, P > 0. 05 ]. However, the level of sFas was significantly higher in the patients with CHF than those of the cardiac function class Ⅰ group [CHF group: 1353. 30 ± 507. 71 (cardiac function class Ⅱ 1154. 85 ± 371.20, class Ⅲ 1412. 88 ± 493. 62, class Ⅳ 1875.67 ± 806. 10) vs. cardiac function class Ⅰ group:983. 11 ± 416.26 pg/ml, P<0. 05]. Conclusion :sFasL was not associated with human CHF. However, the elevation of serum level of sFas was proportionate to the severity of human CHF. sFas may play an important role in the pathogenesis of human CHF.